LigaChem Biosciences리가켐바이오
141080 · KOSDAQ · ₩141080 · 리가켐바이오
₩64,000▼ ₩2,200 (3.32%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 87.6% | 89.0% | 87.3% | 52.1% | 53.4% | 55.0% |
| Operating margin | −208.2% | −75.2% | −16.6% | −236.7% | −150.8% | −86.2% |
| Net margin | −183.6% | −64.7% | 6.2% | −215.9% | −135.0% | −72.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −30.2% | +12.4% | +268.7% | +2.2% | +3.9% | — |
| Operating income growth | −93.2% | −409.2% | +74.1% | −60.4% | −81.8% | — |
| Net income growth | −98.1% | −1,273.7% | +110.6% | −63.5% | −92.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −40.0% | −16.3% | 2.0% | −40.1% | −18.9% | −9.0% |
| Return on assets | −28.0% | −12.7% | 1.7% | −33.3% | −16.5% | −8.0% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 34.7% | 29.7% | 19.9% | 27.9% | 15.0% | 13.3% |
| Net debt to equity | 2.3% | −18.2% | −20.9% | −34.5% | −48.3% | −49.5% |
| Current ratio | 937.1% | 853.5% | 469.6% | 363.1% | 669.9% | 1,345.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: LigaChem Biosciences / 리가켐바이오 / 141080 / KRX:141080
Source: KRX statistical information